BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Free Report) – Research analysts at HC Wainwright lifted their Q2 2025 earnings estimates for shares of BioCryst Pharmaceuticals in a research note issued to investors on Tuesday, May 6th. HC Wainwright analyst A. Fein now expects that the biotechnology company will post earnings per share of $0.10 for the quarter, up from their prior forecast of ($0.01). HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals’ current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.13 EPS, FY2025 earnings at $0.35 EPS, FY2026 earnings at $0.56 EPS, FY2027 earnings at $0.88 EPS and FY2028 earnings at $1.29 EPS.
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Free Report) last posted its quarterly earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to analysts’ expectations of $126.64 million. During the same period in the previous year, the company earned $0.28 earnings per share. The business’s quarterly revenue was up 40.8% on a year-over-year basis.
Check Out Our Latest Analysis on BCRX
BioCryst Pharmaceuticals Stock Up 0.6 %
Shares of NASDAQ BCRX opened at $9.98 on Thursday. BioCryst Pharmaceuticals has a twelve month low of $5.23 and a twelve month high of $11.11. The firm has a market cap of $2.09 billion, a PE ratio of -16.36 and a beta of 1.08. The business has a fifty day simple moving average of $7.87 and a two-hundred day simple moving average of $7.89.
Institutional Trading of BioCryst Pharmaceuticals
A number of institutional investors have recently made changes to their positions in the business. Headlands Technologies LLC acquired a new position in BioCryst Pharmaceuticals during the 1st quarter valued at about $32,000. GF Fund Management CO. LTD. purchased a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth about $33,000. GAMMA Investing LLC increased its holdings in shares of BioCryst Pharmaceuticals by 1,161.8% during the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 5,449 shares in the last quarter. Venturi Wealth Management LLC acquired a new position in shares of BioCryst Pharmaceuticals during the fourth quarter valued at about $46,000. Finally, R Squared Ltd purchased a new position in shares of BioCryst Pharmaceuticals in the 4th quarter valued at approximately $48,000. Institutional investors and hedge funds own 85.88% of the company’s stock.
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
Read More
- Five stocks we like better than BioCryst Pharmaceuticals
- How to Choose Top Rated Stocks
- Google Is Betting Big on Nuclear Reactors—Should You?
- What is a Dividend King?
- Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs
- Quiet Period Expirations Explained
- Why Nearly 20 Analysts Raised Meta Price Targets Post-Earnings
Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.